Pharmaceutical major Strides Pharma Science posted a threefold rise in profit-before-tax (PBT) at Rs 103.6 crore for the third quarter ended December 31. It had posted a pre-tax profit of Rs 27.6 crore in the corresponding period of the previous fiscal.
Led by stellar growth in regulated markets, the Bengaluru-headquartered company posted a 358 per cent rise in net profit at 101 crore as compared to the corresponding quarter of the previous financial year.
“Our contrarian strategies continue to play out for the regulated markets, which are now delivering growth with industry leading post R&D EBITDA margins,” said Arun Kumar, founder of